Publications 2024

Arffman M, Meriranta L, Autio M, Holte H, Jørgensen J, Brown P, Jyrkkiö S, Jerkeman M, Drott K, Fluge Ø, Björkholm M, Karjalainen-Lindsberg ML, Beiske K, Pedersen MØ, Leivonen SK, Leppä S (2024)
Inflammatory and subtype-dependent serum protein signatures predict survival beyond the ctDNA in aggressive B cell lymphomas
Med (in press)
DOI 10.1016/j.medj.2024.03.007, PubMed 38579729

Publications 2023

Ask EH, Tschan-Plessl A, Hoel HJ, Kolstad A, Holte H, Malmberg KJ (2023)
MetaGate: Interactive Analysis of High-Dimensional Cytometry Data with Meta Data Integration
bioRxiv
DOI 10.1101/2023.10.27.564454, PubMed 37961421

Entrop JP, Weibull CE, Smedby KE, Jakobsen LH, Øvlisen AK, Glimelius I, Marklund A, Larsen TS, Holte H, Fosså A, Smeland KB, El-Galaly TC, Eloranta S (2023)
Reproduction patterns among non-Hodgkin lymphoma survivors by subtype in Sweden, Denmark and Norway: A population-based matched cohort study
Br J Haematol, 202 (4), 785-795
DOI 10.1111/bjh.18938, PubMed 37325886

Entrop JP, Weibull CE, Smedby KE, Jakobsen LH, Øvlisen AK, Molin D, Glimelius I, Marklund A, Holte H, Fosså A, Smeland KB, El-Galaly TC, Eloranta S (2023)
Reproduction patterns among classical Hodgkin lymphoma survivors treated with BEACOPP and ABVD in Sweden, Denmark and Norway-A population-based matched cohort study
Int J Cancer, 153 (4), 723-731
DOI 10.1002/ijc.34552, PubMed 37119033

Isaksen KT, Galleberg R, Mastroianni MA, Rinde M, Rusten LS, Barzenje D, Ramslien F, Fluge O, Slaaen M, Meyer P, Liestol K, Smeland EB, Lingjarde OC, Holte H, Brodtkorb M (2023)
The Geriatric Prognostic Index: a clinical prediction model for survival of older diffuse large B-cell lymphoma patients treated with standard immunochemotherapy
Haematologica, 108 (9), 2454-2466
DOI 10.3324/haematol.2022.282289, PubMed 36861406

Kalmbach S, Grau M, Zapukhlyak M, Leich E, Jurinovic V, Hoster E, Staiger AM, Kurz KS, Weigert O, Gaitzsch E, Passerini V, Engelhard M, Herfarth K, Beiske K, Micci F, Möller P, Bernd HW, Feller AC, Klapper W, Stein H, Hansmann ML, Hartmann S, Dreyling M, Holte H, Lenz G et al. (2023)
Novel insights into the pathogenesis of follicular lymphoma by molecular profiling of localized and systemic disease forms
Leukemia, 37 (10), 2058-2065
DOI 10.1038/s41375-023-01995-w, PubMed 37563306

Leich E, Brodtkorb M, Schmidt T, Altenbuchinger M, Lingjærde OC, Lockmer S, Holte H, Nedeva T, Grieb T, Sander B, Sundström C, Spang R, Kimby E, Rosenwald A (2023)
Gene expression and copy number profiling of follicular lymphoma biopsies from patients treated with first-line rituximab without chemotherapy
Leuk Lymphoma, 64 (12), 1927-1937
DOI 10.1080/10428194.2023.2240462, PubMed 37683053

Leivonen SK, Friman T, Autio M, Vaittinen S, Jensen AW, D'Amore F, Hamilton-Dutoit SJ, Holte H, Beiske K, Kovanen PE, Räty R, Leppä S (2023)
Characterization and clinical impact of the tumor microenvironment in post-transplant aggressive B-cell lymphomas
Haematologica, 108 (11), 3044-3057
DOI 10.3324/haematol.2023.282831, PubMed 37259566

Ludvigsen M, Campbell AJ, Enemark MB, Hybel TE, Karjalainen-Lindsberg ML, Beiske K, Bjerre M, Pedersen LM, Holte H, Leppä S, Jørgensen JM, Honoré B (2023)
Proteomics uncovers molecular features for relapse risk stratification in patients with diffuse large B-cell lymphoma
Blood Cancer J, 13 (1), 161
DOI 10.1038/s41408-023-00931-6, PubMed 37884514

Ramsower CA, Rosenthal A, Robetorye RS, Mwangi R, Maurer M, Villa D, McDonnell T, Feldman A, Cohen JB, Habermann T, Campo E, Clot G, Bühler MM, Kulis M, Martin-Subero JI, Giné E, Cook JR, Hill B, Raess PW, Beiske KH, Reichart A, Hartmann S, Holte H, Scott D, Rimsza L (2023)
Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine-rituximab
Br J Haematol, 204 (1), 160-170
DOI 10.1111/bjh.19153, PubMed 37881141

Salim R, Husby S, Winther Eskelund C, Scott DW, Holte H, Kolstad A, Räty R, Ek S, Jerkeman M, Geisler C, Sommer Kristensen L, Dahl M, Grønbæk K (2023)
Exploring new prognostic biomarkers in Mantle Cell Lymphoma: a comparison of the circSCORE and the MCL35 score
Leuk Lymphoma, 64 (8), 1414-1423
DOI 10.1080/10428194.2023.2216819, PubMed 37259807

Spasevska I, Sharma A, Steen CB, Josefsson SE, Blaker YN, Kolstad A, Rustad EH, Meyer S, Isaksen K, Chellappa S, Kushekhar K, Beiske K, Førsund MS, Spetalen S, Holte H, Østenstad B, Brodtkorb M, Kimby E, Olweus J, Taskén K, Newman AM, Lorenz S, Smeland EB, Alizadeh AA, Huse K et al. (2023)
Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma
Blood Adv, 7 (23), 7216-7230
DOI 10.1182/bloodadvances.2023010158, PubMed 37695745

Publications 2022

Meriranta L, Alkodsi A, Pasanen A, Lepistö M, Mapar P, Blaker YN, Jørgensen J, Karjalainen-Lindsberg ML, Fiskvik I, Mikalsen LTG, Autio M, Björkholm M, Jerkeman M, Fluge Ø, Brown P, Jyrkkiö S, Holte H, Pitkänen E, Ellonen P, Leppä S (2022)
Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma
Blood, 139 (12), 1863-1877
DOI 10.1182/blood.2021012852, PubMed 34932792

Smeland K, Holte H, Fagerli UM, Bersvendsen H, Hjermstad MJ, Loge JH, Murbrach K, Linnsund MD, Fluge O, Stenehjem JS, Lund MB, Kvaloy S, Kiserud CE (2022)
Total late effect burden in long-term lymphoma survivors after high-dose therapy with autologous stem-cell transplant and its effect on health-related quality of life
Haematologica, 107 (11), 2698-2707
DOI 10.3324/haematol.2021.280413, PubMed 35484681

Vajavaara H, Leivonen SK, Jørgensen J, Holte H, Leppä S (2022)
Low lymphocyte-to-monocyte ratio predicts poor outcome in high-risk aggressive large B-cell lymphoma
EJHaem, 3 (3), 681-687
DOI 10.1002/jha2.409, PubMed 36051040

Publications 2021

Alonso-Álvarez S, Manni M, Montoto S, Sarkozy C, Morschhauser F, Wondergem MJ, Guarini A, Magnano L, Alcoceba M, Chamuleau M, Galimberti S, Gomes da Silva M, Holte H, Zucca E, Lockmer S, Aurer I, Marcheselli L, Stepanishyna Y, Caballero Barrigón MD, Salles G, Federico M (2021)
Primary refractory follicular lymphoma: a poor outcome entity with high risk of transformation to aggressive B cell lymphoma
Eur J Cancer, 157, 132-139
DOI 10.1016/j.ejca.2021.08.005, PubMed 34508995

Autio M, Leivonen SK, Brück O, Mustjoki S, Mészáros Jørgensen J, Karjalainen-Lindsberg ML, Beiske K, Holte H, Pellinen T, Leppä S (2021)
Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma
Haematologica, 106 (3), 718-729
DOI 10.3324/haematol.2019.243626, PubMed 32079690

Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, Kato K, Sureda A, Greil R, Thieblemont C, Morschhauser F, Janz M, Flinn I, Rabitsch W, Kwong YL, Kersten MJ, Minnema MC, Holte H, Chan EHL, Martinez-Lopez J, Müller AMS, Maziarz RT, McGuirk JP, Bachy E, Le Gouill S et al. (2021)
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
N Engl J Med, 386 (7), 629-639
DOI 10.1056/NEJMoa2116596, PubMed 34904798

Isaksen KT, Mastroianni MA, Rinde M, Rusten LS, Barzenje DA, Ramslien LF, Slaaen M, Jerm MB, Smeland EB, Rostoft S, Liestøl K, Brodtkorb M, Holte H (2021)
A simplified frailty score predicts survival and can aid treatment-intensity decisions in older patients with DLBCL
Blood Adv, 5 (22), 4771-4782
DOI 10.1182/bloodadvances.2021004777, PubMed 34543384

Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, Waller EK, Jaglowski S, Bishop MR, Damon LE, Foley SR, Westin JR, Fleury I, Ho PJ, Mielke S, Teshima T, Janakiram M, Hsu JM, Izutsu K, Kersten MJ, Ghosh M, Wagner-Johnston N, Kato K, Corradini P, Martinez-Prieto M et al. (2021)
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study
Lancet Oncol, 22 (10), 1403-1415
DOI 10.1016/S1470-2045(21)00375-2, PubMed 34516954

Vajavaara H, Ekeblad F, Holte H, Jorgensen J, Leivonen SK, Berglund M, Kamper P, Moller HJ, D'Amore F, Molin D, Enblad G, Ludvigsen M, Glimelius I, Leppa S (2021)
Prognostic impact of soluble CD163 in patients with diffuse large B-cell lymphoma
Haematologica, 106 (9), 2502-2506
DOI 10.3324/haematol.2020.278182, PubMed 33764002

Vajavaara H, Mortensen JB, Leivonen SK, Hansen IM, Ludvigsen M, Holte H, Jørgensen J, Bjerre M, d'Amore F, Leppä S (2021)
Soluble PD-1 but Not PD-L1 Levels Predict Poor Outcome in Patients with High-Risk Diffuse Large B-Cell Lymphoma
Cancers (Basel), 13 (3)
DOI 10.3390/cancers13030398, PubMed 33499013

Publications 2020

Ask EH, Tschan-Plessl A, Gjerdingen TJ, Sætersmoen ML, Hoel HJ, Wiiger MT, Olweus J, Wahlin BE, Lingjærde OC, Horowitz A, Cashen AF, Watkins M, Fehniger TA, Holte H, Kolstad A, Malmberg KJ (2020)
A Systemic Protein Deviation Score Linked to PD-1⁺ CD8⁺ T Cell Expansion That Predicts Overall Survival in Diffuse Large B Cell Lymphoma
Med, 2 (2), 180-195.e5
DOI 10.1016/j.medj.2020.10.006, PubMed 35590201

Bersvendsen HS, Haugnes HS, Dahl AA, Fagerli UM, Fluge Ø, Holte H, Wilsgaard T, Smeland KB, Kiserud CE (2020)
Sexual dysfunction is prevalent in female lymphoma survivors after autologous stem-cell transplantation and is associated with younger age, chronic fatigue, and mental distress
Bone Marrow Transplant, 56 (4), 968-970
DOI 10.1038/s41409-020-01098-5, PubMed 33139869

Isaksen KT, Beiske K, Smeland EB, Jørgensen J, Brodtkorb M, Myklebust JH, Jerkeman M, Meriranta L, Karjalainen-Lindsberg ML, Leppä S, Scott DW, Holte H, Blaker YN (2020)
The DLBCL90 gene-expression assay identifies double-hit lymphomas with high sensitivity in patients from two phase II clinical trials with high-risk diffuse large B-cell lymphoma
EJHaem, 2 (1), 104-108
DOI 10.1002/jha2.109, PubMed 35846101

Jakobsen LH, Ellin F, Smeland KB, Wästerlid T, Christensen JH, Jørgensen JM, Josefsson PL, Øvlisen AK, Holte H, Blaker YN, Grauslund JH, Bjørn J, Molin D, Lagerlöf I, Smedby KE, Colvin K, Thanarajasingam G, Maurer MJ, Habermann TM, Song KW, Zhu KY, Gerrie AS, Cheah CY, El-Galaly TC (2020)
Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients
Br J Haematol, 189 (4), 661-671
DOI 10.1111/bjh.16425, PubMed 32017050

Kimby E, Lockmer S, Holte H, Hagberg H, Wahlin BE, Brown P, Østenstad B (2020)
The simplified follicular lymphoma PRIMA-prognostic index is useful in patients with first-line chemo-free rituximab-based therapy
Br J Haematol, 191 (5), 738-747
DOI 10.1111/bjh.16692, PubMed 32410260

Kolstad A, Illidge T, Bolstad N, Spetalen S, Madsbu U, Stokke C, Blakkisrud J, Løndalen A, O'Rourke N, Beasley M, Jurczak W, Fagerli UM, Kaščák M, Bayne M, Obr A, Dahle J, Rojkjaer L, Pascal V, Holte H (2020)
Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma
Blood Adv, 4 (17), 4091-4101
DOI 10.1182/bloodadvances.2020002583, PubMed 32877524

Leppä S, Jørgensen J, Tierens A, Meriranta L, Østlie I, de Nully Brown P, Fagerli UM, Larsen TS, Mannisto S, Munksgaard L, Maisenhölder M, Vasala K, Meyer P, Jerkeman M, Björkholm M, Fluge Ø, Jyrkkiö S, Liestøl K, Ralfkiaer E, Spetalen S, Beiske K, Karjalainen-Lindsberg ML, Holte H (2020)
Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis
Blood Adv, 4 (9), 1906-1915
DOI 10.1182/bloodadvances.2020001518, PubMed 32380536

Maziarz RT, Waller EK, Jaeger U, Fleury I, McGuirk J, Holte H, Jaglowski S, Schuster SJ, Bishop MR, Westin JR, Mielke S, Teshima T, Bachanova V, Foley SR, Borchmann P, Salles GA, Zhang J, Tiwari R, Pacaud LB, Ma Q, Tam CS (2020)
Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma
Blood Adv, 4 (4), 629-637
DOI 10.1182/bloodadvances.2019001026, PubMed 32074277

Wise JF, Nakken S, Steen CB, Vodák D, Trøen G, Johannessen B, Lingjærde OC, Hilden V, Blaker YN, Bai B, Aasheim LB, Pasanen A, Lorenz S, Sveen A, Lothe RA, Myklebost O, Leppä S, Meza-Zepeda LA, Beiske K, Lawrence MS, Hovig E, Myklebust JH, Smeland EB, Holte H (2020)
Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series
Blood Adv, 4 (9), 1859-1866
DOI 10.1182/bloodadvances.2019001325, PubMed 32374878

Publications 2019

Alkodsi A, Cervera A, Zhang K, Louhimo R, Meriranta L, Pasanen A, Leivonen SK, Holte H, Leppä S, Lehtonen R, Hautaniemi S (2019)
Distinct subtypes of diffuse large B-cell lymphoma defined by hypermutated genes
Leukemia, 33 (11), 2662-2672
DOI 10.1038/s41375-019-0509-6, PubMed 31186494

Bersvendsen HS, Haugnes HS, Dahl AA, Fagerli UM, Fluge Ø, Holte H, Seland M, Wilsgaard T, Smeland KB, Kiserud CE (2019)
Sexual function in long-term male lymphoma survivors after high-dose therapy with autologous stem-cell transplantation
Bone Marrow Transplant, 55 (5), 891-905
DOI 10.1038/s41409-019-0745-4, PubMed 31745250

Bersvendsen HS, Haugnes HS, Fagerli UM, Fluge Ø, Holte H, Smeland KB, Wilsgaard T, Kiserud CE (2019)
Lifestyle behavior among lymphoma survivors after high-dose therapy with autologous hematopoietic stem cell transplantation, assessed by patient-reported outcomes
Acta Oncol, 58 (5), 690-699
DOI 10.1080/0284186X.2018.1558370, PubMed 30696346

Biccler JL, Glimelius I, Eloranta S, Smeland KB, Brown PN, Jakobsen LH, Frederiksen H, Jerkeman M, Fosså A, Andersson TML, Holte H, Bøgsted M, El-Galaly TC, Smedby KE (2019)
Relapse Risk and Loss of Lifetime After Modern Combined Modality Treatment of Young Patients With Hodgkin Lymphoma: A Nordic Lymphoma Epidemiology Group Study
J Clin Oncol, 37 (9), 703-713
DOI 10.1200/JCO.18.01652, PubMed 30726176

Bishop MR, Maziarz RT, Waller EK, Jäger U, Westin JR, McGuirk JP, Fleury I, Holte H, Borchmann P, Del Corral C, Tiwari R, Anak Ö, Awasthi R, Pacaud L, Romanov VV, Schuster SJ (2019)
Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion
Blood Adv, 3 (14), 2230-2236
DOI 10.1182/bloodadvances.2019000151, PubMed 31332046

Fosså A, Smeland K, Fagerli UM, Galleberg RB, Bersvendsen HS, Holte H (2019)
Brentuximab vedotin in relapsed or refractory classical hodgkin lymphoma: real life experience in Norway 2011-2016
Acta Oncol, 59 (1), 101-105
DOI 10.1080/0284186X.2019.1652765, PubMed 31429371

Josefsson SE, Beiske K, Blaker YN, Førsund MS, Holte H, Østenstad B, Kimby E, Köksal H, Wälchli S, Bai B, Smeland EB, Levy R, Kolstad A, Huse K, Myklebust JH (2019)
TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma
Cancer Immunol Res, 7 (3), 355-362
DOI 10.1158/2326-6066.CIR-18-0351, PubMed 30659053

Köksal H, Dillard P, Josefsson SE, Maggadottir SM, Pollmann S, Fåne A, Blaker YN, Beiske K, Huse K, Kolstad A, Holte H, Kvalheim G, Smeland EB, Myklebust JH, Inderberg EM, Wälchli S (2019)
Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma
Blood Adv, 3 (8), 1230-1243
DOI 10.1182/bloodadvances.2018029678, PubMed 30979721

Lagerlöf I, Holte H, Glimelius I, Björkholm M, Enblad G, Erlanson M, Fluge Ø, Fohlin H, Fosså A, Goldkuhl C, Gustavsson A, Johansson AS, Linderoth J, Nome O, Palma M, Åkesson L, Østenstad B, Raud C, Glimelius B, Molin D (2019)
No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy
Br J Haematol, 188 (5), 685-691
DOI 10.1111/bjh.16232, PubMed 31612478

Lockmer S, Østenstad B, Hagberg H, Holte H, Wahlin BE, Wader KF, Smedby KE, Brown P, Kimby E (2019)
Reply to M. Sorigue et al
J Clin Oncol, 37 (9), 759-760
DOI 10.1200/JCO.18.02362, PubMed 30735430

Poeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, Borchmann P, Viardot A, Soekler M, Keller U, Schmidt C, Truemper L, Mahlberg R, Marks R, Hoeffkes HG, Metzner B, Dierlamm J, Frickhofen N, Haenel M, Neubauer A, Kneba M, Merli F, Tucci A, de Nully Brown P, Federico M et al. (2019)
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial
Lancet, 394 (10216), 2271-2281
DOI 10.1016/S0140-6736(19)33008-9, PubMed 31868632

Steen CB, Leich E, Myklebust JH, Lockmer S, Wise JF, Wahlin BE, Østenstad B, Liestøl K, Kimby E, Rosenwald A, Smeland EB, Holte H, Lingjærde OC, Brodtkorb M (2019)
A clinico-molecular predictor identifies follicular lymphoma patients at risk of early transformation after first-line immunotherapy
Haematologica, 104 (10), e460-e464
DOI 10.3324/haematol.2018.209080, PubMed 30846496

Publications 2018

Da Broi M, Jahr G, Beiske K, Holte H, Meling TR (2018)
Efficacy of the Nordic and the MSKCC chemotherapy protocols on the overall and progression-free survival in intracranial PCNSL
Blood Cells Mol Dis, 73, 25-32
DOI 10.1016/j.bcmd.2018.08.005, PubMed 30217760

Federico M, Caballero Barrigón MD, Marcheselli L, Tarantino V, Manni M, Sarkozy C, Alonso-Álvarez S, Wondergem M, Cartron G, Lopez-Guillermo A, Issa D, Morschhauser F, Alcoceba M, Kimby E, Rusconi C, Chamuleau M, Holte H, Lockmer S, Montoto S, Gomes da Silva M, Aurer I, Zucca E, Paszkiewicz-Kozik E, Minoia C, Skrypets T et al. (2018)
Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis
Lancet Haematol, 5 (8), e359-e367
DOI 10.1016/S2352-3026(18)30090-5, PubMed 30078408

Holte H, Beiske K, Boyle M, Trøen G, Blaker YN, Myklebust J, Kvaløy S, Rosenwald A, Lingjaerde OC, Rimsza LM, Smeland EB, Scott DW, Kolstad A (2018)
The MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy
Br J Haematol, 183 (2), 225-234
DOI 10.1111/bjh.15518, PubMed 30080252

Jahr G, Broi MD, Holte H, Beiske K, Meling TR (2018)
Evaluation of Memorial Sloan-Kettering Cancer Center and International Extranodal Lymphoma Study Group prognostic scoring systems to predict Overall Survival in intracranial Primary CNS lymphoma
Brain Behav, 8 (3), e00928
DOI 10.1002/brb3.928, PubMed 29541540

Jahr G, Da Broi M, Holte H, Beiske K, Meling TR (2018)
The role of surgery in intracranial PCNSL
Neurosurg Rev, 41 (4), 1037-1044
DOI 10.1007/s10143-018-0946-0, PubMed 29383600

Lockmer S, Østenstad B, Hagberg H, Holte H, Johansson AS, Wahlin BE, Wader KF, Steen CB, Meyer P, Maisenhølder M, Smedby KE, Brown P, Kimby E (2018)
Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up
J Clin Oncol, 36 (33), 3315-+
DOI 10.1200/JCO.18.00262, PubMed 30285560

Meling TR, Latysheva A, Da Broi M, Jahr G, Holte H, Beiske K, Emblem KE (2018)
Is deep brain involvement in intracranial primary central nervous system lymphoma of importance for penetration of chemotherapeutic agents?
Neuroradiology, 60 (7), 703-713
DOI 10.1007/s00234-018-2038-9, PubMed 29804159

Mottok A, Wright G, Rosenwald A, Ott G, Ramsower C, Campo E, Braziel RM, Delabie J, Weisenburger DD, Song JY, Chan WC, Cook JR, Fu K, Greiner T, Smeland E, Holte H, Savage KJ, Glinsmann-Gibson BJ, Gascoyne RD, Staudt LM, Jaffe ES, Connors JM, Scott DW, Steidl C, Rimsza LM (2018)
Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens
Blood, 132 (22), 2401-2405
DOI 10.1182/blood-2018-05-851154, PubMed 30257882

Rauert-Wunderlich H, Mottok A, Scott DW, Rimsza LM, Ott G, Klapper W, Unterhalt M, Kluin-Nelemans HC, Hermine O, Hartmann S, Thorns C, Rymkiewicz G, Holte H, Dreyling M, Hoster E, Rosenwald A (2018)
Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network
Br J Haematol, 184 (4), 616-624
DOI 10.1111/bjh.15519, PubMed 30095158

Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin JR, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Pantano S, Pacaud LB, Awasthi R, Chu J, Anak Ö, Salles G, Maziarz RT, JULIET Investigators (2018)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
N Engl J Med, 380 (1), 45-56
DOI 10.1056/NEJMoa1804980, PubMed 30501490

Smeland KB, Loge JH, Aass HCD, Aspelin T, Bersvendsen H, Bolstad N, Fagerli UM, Falk RS, Fluge Ø, Fosså A, Holte H, Lund MB, Murbræch K, Reinertsen KV, Stenehjem JS, Kiserud CE (2018)
Chronic fatigue is highly prevalent in survivors of autologous stem cell transplantation and associated with IL-6, neuroticism, cardiorespiratory fitness, and obesity
Bone Marrow Transplant, 54 (4), 607-610
DOI 10.1038/s41409-018-0342-y, PubMed 30262906

Stokke C, Blakkisrud J, Løndalen A, Dahle J, Martinsen ACT, Holte H, Kolstad A (2018)
Pre-dosing with lilotomab prior to therapy with ¹⁷⁷Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients
Eur J Nucl Med Mol Imaging, 45 (7), 1233-1241
DOI 10.1007/s00259-018-3964-9, PubMed 29470615

Straumann GSH, Austvoll-Dahlgren A, Holte HH, Wisborg T (2018)
Effect of requiring a general practitioner at scenes of serious injury: A systematic review
Acta Anaesthesiol Scand, 62 (9), 1194-1199
DOI 10.1111/aas.13174, PubMed 29932207

Vodák D, Lorenz S, Nakken S, Aasheim LB, Holte H, Bai B, Myklebost O, Meza-Zepeda LA, Hovig E (2018)
Sample-Index Misassignment Impacts Tumour Exome Sequencing
Sci Rep, 8 (1), 5307
DOI 10.1038/s41598-018-23563-4, PubMed 29593270

Publications 2017

Barzenje DA, Kolstad A, Ghanima W, Holte H (2017)
Long-term outcome of patients with solitary plasmacytoma treated with radiotherapy: A population-based, single-center study with median follow-up of 13.7 years
Hematol Oncol, 36 (1), 217-223
DOI 10.1002/hon.2415, PubMed 28393375

Blakkisrud J, Holtedahl JE, Løndalen A, Dahle J, Bach-Gansmo T, Holte H, Nygaard S, Kolstad A, Stokke C (2017)
Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody-Radionuclide Conjugate ¹⁷⁷Lu-Lilotomab Satetraxetan
J Nucl Med, 59 (4), 704-710
DOI 10.2967/jnumed.117.195347, PubMed 28848035

Leivonen SK, Icay K, Jäntti K, Siren I, Liu C, Alkodsi A, Cervera A, Ludvigsen M, Hamilton-Dutoit SJ, d'Amore F, Karjalainen-Lindsberg ML, Delabie J, Holte H, Lehtonen R, Hautaniemi S, Leppä S (2017)
MicroRNAs regulate key cell survival pathways and mediate chemosensitivity during progression of diffuse large B-cell lymphoma
Blood Cancer J, 7 (12), 654
DOI 10.1038/s41408-017-0033-8, PubMed 29242506

Leivonen SK, Taskinen M, Cervera A, Karjalainen-Lindsberg ML, Delabie J, Holte H, Lehtonen R, Hautaniemi S, Leppä S (2017)
Alternative splicing discriminates molecular subtypes and has prognostic impact in diffuse large B-cell lymphoma
Blood Cancer J, 7 (8), e596
DOI 10.1038/bcj.2017.71, PubMed 28841210

Meriranta L, Pasanen A, Louhimo R, Cervera A, Alkodsi A, Autio M, Taskinen M, Rantanen V, Karjalainen-Lindsberg ML, Holte H, Delabie J, Lehtonen R, Hautaniemi S, Leppä S (2017)
Deltex-1 mutations predict poor survival in diffuse large B-cell lymphoma
Haematologica, 102 (5), e195-e198
DOI 10.3324/haematol.2016.157495, PubMed 28183850

Scott DW, Abrisqueta P, Wright GW, Slack GW, Mottok A, Villa D, Jares P, Rauert-Wunderlich H, Royo C, Clot G, Pinyol M, Boyle M, Chan FC, Braziel RM, Chan WC, Weisenburger DD, Cook JR, Greiner TC, Fu K, Ott G, Delabie J, Smeland EB, Holte H, Jaffe ES, Steidl C et al. (2017)
New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies
J Clin Oncol, 35 (15), 1668-1677
DOI 10.1200/JCO.2016.70.7901, PubMed 28291392

Seland M, Smeland KB, Bjøro T, Falk RS, Fosså SD, Gjesdal CG, Godang K, Holte H, Svartberg J, Syversen U, Bollerslev J, Kiserud CE (2017)
Bone mineral density is close to normal for age in long-term lymphoma survivors treated with high-dose therapy with autologous stem cell transplantation
Acta Oncol, 56 (4), 590-598
DOI 10.1080/0284186X.2016.1267870, PubMed 28077016

Stenehjem JS, Smeland KB, Murbraech K, Holte H, Kvaløy SO, Wethal T, Kiserud CE, Samersaw-Lund MB (2017)
Obstructive and restrictive pulmonary dysfunction in long-term lymphoma survivors after high-dose therapy with autologous stem cell transplantation
Acta Oncol, 57 (6), 773-781
DOI 10.1080/0284186X.2017.1406137, PubMed 29171324

Publications 2016

Barzenje DA, Holte H, Fosså A, Ghanima W, Liestøl K, Delabie J, Kolstad A (2016)
Long-term outcome for patients with early stage marginal zone lymphoma and mantle cell lymphoma
Leuk Lymphoma, 58 (3), 623-632
DOI 10.1080/10428194.2016.1204653, PubMed 27389974

Blaker YN, Spetalen S, Brodtkorb M, Lingjaerde OC, Beiske K, Østenstad B, Sander B, Wahlin BE, Melen CM, Myklebust JH, Holte H, Delabie J, Smeland EB (2016)
The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era
Br J Haematol, 175 (1), 102-14
DOI 10.1111/bjh.14201, PubMed 27341313

Blakkisrud J, Løndalen A, Dahle J, Turner S, Holte H, Kolstad A, Stokke C (2016)
Red Marrow-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody-Radionuclide Conjugate
J Nucl Med, 58 (1), 55-61
DOI 10.2967/jnumed.116.180471, PubMed 27587710

Blakkisrud J, Løndalen A, Martinsen AC, Dahle J, Holtedahl JE, Bach-Gansmo T, Holte H, Kolstad A, Stokke C (2016)
Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan
J Nucl Med, 58 (1), 48-54
DOI 10.2967/jnumed.116.173922, PubMed 27493270

Coiffier B, Thieblemont C, de Guibert S, Dupuis J, Ribrag V, Bouabdallah R, Morschhauser F, Navarro R, Le Gouill S, Haioun C, Houot R, Casasnovas O, Holte H, Lamy T, Broussais F, Payrard S, Hatteville L, Tilly H (2016)
A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma
Br J Haematol, 173 (5), 722-30
DOI 10.1111/bjh.13992, PubMed 27010483

Kiserud CE, Fagerli UM, Smeland KB, Fluge Ø, Bersvendsen H, Kvaløy S, Holte H, Dahl AA (2016)
Pattern of employment and associated factors in long-term lymphoma survivors 10 years after high-dose chemotherapy with autologous stem cell transplantation
Acta Oncol, 55 (5), 547-53
DOI 10.3109/0284186X.2015.1125015, PubMed 27123741

Murbraech K, Holte E, Broch K, Smeland KB, Holte H, Rösner A, Lund MB, Dalen H, Kiserud C, Aakhus S (2016)
Impaired Right Ventricular Function in Long-Term Lymphoma Survivors
J Am Soc Echocardiogr, 29 (6), 528-36
DOI 10.1016/j.echo.2016.02.014, PubMed 27038515

Murbraech K, Wethal T, Smeland KB, Holte H, Loge JH, Holte E, Rösner A, Dalen H, Kiserud CE, Aakhus S (2016)
Valvular Dysfunction in Lymphoma Survivors Treated With Autologous Stem Cell Transplantation: A National Cross-Sectional Study
JACC Cardiovasc Imaging, 9 (3), 230-9
DOI 10.1016/j.jcmg.2015.06.028, PubMed 26897666

Pauly F, Fjordén K, Leppä S, Holte H, Björkholm M, Fluge Ø, Møller Pedersen L, Eriksson M, Isinger-Ekstrand A, Borrebaeck CA, Jerkeman M, Wingren C (2016)
Plasma immunoprofiling of patients with high-risk diffuse large B-cell lymphoma: a Nordic Lymphoma Group study
Blood Cancer J, 6 (11), e501
DOI 10.1038/bcj.2016.113, PubMed 27858932

Smeland KB, Kiserud CE, Lauritzsen GF, Blystad AK, Fagerli UM, Falk RS, Fluge Ø, Fosså A, Kolstad A, Loge JH, Maisenhölder M, Østenstad B, Kvaløy S, Holte H (2016)
A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma
Br J Haematol, 173 (3), 432-43
DOI 10.1111/bjh.13965, PubMed 26914167

Stenehjem JS, Smeland KB, Murbraech K, Holte H, Kvaløy S, Thorsen L, Arbo I, Jones LW, Aakhus S, Lund MB, Kiserud CE (2016)
Cardiorespiratory fitness in long-term lymphoma survivors after high-dose chemotherapy with autologous stem cell transplantation
Br J Cancer, 115 (2), 178-87
DOI 10.1038/bjc.2016.180, PubMed 27351215

Stenehjem JS, Smeland KB, Murbraech K, Holte H, Kvaløy S, Wethal T, Kiserud CE, Lund MB (2016)
Diffusing capacity impairment is prevalent in long-term lymphoma survivors after high-dose therapy with autologous stem cell transplantation
Bone Marrow Transplant, 52 (4), 646-649
DOI 10.1038/bmt.2016.338, PubMed 27991891

Torfoss D, Fladhagen T, Holte H, Brinch L, Schjesvold FH, Fløisand Y, Nyquist E, Dalgaard J, Meyer P, Lehmann AK, Hammerstrøm J, Skjelbakken T, Høiby EA, Sandvik L, Kvaløy S (2016)
Benzylpenicillin plus an aminoglycoside versus meropenem in neutropenic lymphoma and leukaemia patients with a suspected bacterial infection: a randomized, controlled trial
Clin Microbiol Infect, 23 (3), 179-187
DOI 10.1016/j.cmi.2016.10.019, PubMed 27793737

Publications 2015

Barzenje DA, Cvancarova Småstuen M, Liestøl K, Fosså A, Delabie J, Kolstad A, Holte H (2015)
Radiotherapy Compared to Other Strategies in the Treatment of Stage I/II Follicular Lymphoma: A Study of 404 Patients with a Median Follow-Up of 15 Years
PLoS One, 10 (7), e0131158
DOI 10.1371/journal.pone.0131158, PubMed 26147646

Blaker YN, Brodtkorb M, Maddison J, Hveem TS, Nesheim JA, Mohn HM, Kolstad A, Geisler CH, Liestøl K, Smeland EB, Holte H, Delabie J, Danielsen H (2015)
Computerized image analysis of the Ki-67 proliferation index in mantle cell lymphoma
Histopathology, 67 (1), 62-9
DOI 10.1111/his.12624, PubMed 25431344

Kimby E, Östenstad B, Brown P, Hagberg H, Erlanson M, Holte H, Linden O, Johansson AS, Ahlgren T, Wader K, Wahlin BE, Delabie J, Sundström C, Nordic Lymphoma Group (NLG) (2015)
Two courses of four weekly infusions of rituximab with or without interferon-α2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas
Leuk Lymphoma, 56 (9), 2598-607
DOI 10.3109/10428194.2015.1014363, PubMed 25686644

Malecka A, Tierens A, Østlie I, Schmitz R, Trøen G, Spetalen S, Staudt LM, Smeland E, Holte H, Delabie J (2015)
Primary diffuse large B-cell lymphoma associated with clonally-related monoclonal B lymphocytosis indicates a common precursor cell
Haematologica, 100 (10), e415-8
DOI 10.3324/haematol.2015.126656, PubMed 26001788

Murbraech K, Smeland KB, Holte H, Loge JH, Lund MB, Wethal T, Holte E, Rösner A, Dalen H, Kvaløy S, Falk RS, Aakhus S, Kiserud CE (2015)
Heart Failure and Asymptomatic Left Ventricular Systolic Dysfunction in Lymphoma Survivors Treated With Autologous Stem-Cell Transplantation: A National Cross-Sectional Study
J Clin Oncol, 33 (24), 2683-91
DOI 10.1200/JCO.2015.60.8125, PubMed 26169610

Seland M, Bjøro T, Furre T, Schreiner T, Bollerslev J, Fosså SD, Loge JH, Holte H, Kiserud CE (2015)
Hormonal dysfunction is frequent in cancer survivors treated with radiotherapy to the head and neck region
J Cancer Surviv, 9 (4), 630-40
DOI 10.1007/s11764-015-0439-x, PubMed 25750158

Seland M, Holte H, Bjøro T, Schreiner T, Bollerslev J, Loge JH, Fosså SD, Kiserud CE (2015)
Chronic fatigue is prevalent and associated with hormonal dysfunction in long-term non-Hodgkin lymphoma survivors treated with radiotherapy to the head and neck region
Leuk Lymphoma, 56 (12), 3306-14
DOI 10.3109/10428194.2015.1036258, PubMed 25827172

Smeland KB, Kiserud CE, Lauritzsen GF, Fagerli UM, Falk RS, Fluge Ø, Fosså A, Kolstad A, Loge JH, Maisenhölder M, Kvaløy S, Holte H (2015)
Conditional survival and excess mortality after high-dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway
Haematologica, 100 (6), e240-3
DOI 10.3324/haematol.2014.119214, PubMed 25682605

Publications 2014

Bethge N, Honne H, Andresen K, Hilden V, Trøen G, Liestøl K, Holte H, Delabie J, Lind GE, Smeland EB (2014)
A gene panel, including LRP12, is frequently hypermethylated in major types of B-cell lymphoma
PLoS One, 9 (9), e104249
DOI 10.1371/journal.pone.0104249, PubMed 25226156

Blaker YN, Eide MB, Liestøl K, Lauritzsen GF, Kolstad A, Fosså A, Smeland EB, Holte H (2014)
High dose chemotherapy with autologous stem cell transplant for patients with transformed B-cell non-Hodgkin lymphoma in the rituximab era
Leuk Lymphoma, 55 (10), 2319-27
DOI 10.3109/10428194.2013.871632, PubMed 24432894

Fiskvik I, Beiske K, Delabie J, Yri O, Spetalen S, Karjalainen-Lindsberg ML, Leppä S, Liestøl K, Smeland EB, Holte H (2014)
Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma
Leuk Lymphoma, 56 (6), 1742-9
DOI 10.3109/10428194.2014.970550, PubMed 25284491

Hagtvedt T, Seierstad T, Lund KV, Løndalen AM, Bogsrud TV, Smith HJ, Geier OM, Holte H, Aaløkken TM (2014)
Diffusion-weighted MRI compared to FDG PET/CT for assessment of early treatment response in lymphoma
Acta Radiol, 56 (2), 152-8
DOI 10.1177/0284185114526087, PubMed 24585944

Kiserud CE, Seland M, Holte H, Fosså A, Fosså SD, Bollerslev J, Bjøro T, Loge JH (2014)
Fatigue in male lymphoma survivors differs between diagnostic groups and is associated with latent hypothyroidism
Acta Oncol, 54 (1), 49-59
DOI 10.3109/0284186X.2014.948057, PubMed 25140862

Kolstad A, Kumari S, Walczak M, Madsbu U, Hagtvedt T, Bogsrud TV, Kvalheim G, Holte H, Aurlien E, Delabie J, Tierens A, Olweus J (2014)
Sequential intranodal immunotherapy induces antitumor immunity and correlated regression of disseminated follicular lymphoma
Blood, 125 (1), 82-9
DOI 10.1182/blood-2014-07-592162, PubMed 25293773

Mylam KJ, Kostakoglu L, Hutchings M, Coleman M, Lamonica D, Czuczman MS, Diehl LF, Nielsen AL, Jensen P, Loft A, Hendel HW, Iyer V, Leppä S, Jyrkkiö S, Holte H, Eriksson M, Gillstrøm D, Hansen PB, Seppänen M, Hjorthaug K, Brown Pde N, Pedersen LM (2014)
(18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study
Leuk Lymphoma, 56 (7), 2005-12
DOI 10.3109/10428194.2014.975800, PubMed 25330442

Riihijärvi S, Fiskvik I, Taskinen M, Vajavaara H, Tikkala M, Yri O, Karjalainen-Lindsberg ML, Delabie J, Smeland E, Holte H, Leppä S (2014)
Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial
Haematologica, 100 (2), 238-45
DOI 10.3324/haematol.2014.113472, PubMed 25381134

Taskinen M, Louhimo R, Koivula S, Chen P, Rantanen V, Holte H, Delabie J, Karjalainen-Lindsberg ML, Björkholm M, Fluge Ø, Pedersen LM, Fjordén K, Jerkeman M, Eriksson M, Hautaniemi S, Leppä S (2014)
Deregulation of COMMD1 is associated with poor prognosis in diffuse large B-cell lymphoma
PLoS One, 9 (3), e91031
DOI 10.1371/journal.pone.0091031, PubMed 24625556

Publications 2013

Bersvendsen H, Kolstad A, Blystad AK, Aurlien E, Fosså A, Kvaløy SO, Holte H, Lauritzsen GF (2013)
Multimodal treatment with ALL-like chemotherapy, Auto-SCT and radiotherapy for lymphoblastic lymphoma
Acta Oncol, 53 (5), 680-7
DOI 10.3109/0284186X.2013.855816, PubMed 24237392

Bethge N, Honne H, Hilden V, Trøen G, Eknæs M, Liestøl K, Holte H, Delabie J, Smeland EB, Lind GE (2013)
Identification of highly methylated genes across various types of B-cell non-hodgkin lymphoma
PLoS One, 8 (11), e79602
DOI 10.1371/journal.pone.0079602, PubMed 24260260

Bethge N, Lothe RA, Honne H, Andresen K, Trøen G, Eknæs M, Liestøl K, Holte H, Delabie J, Smeland EB, Lind GE (2013)
Colorectal cancer DNA methylation marker panel validated with high performance in Non-Hodgkin lymphoma
Epigenetics, 9 (3), 428-36
DOI 10.4161/epi.27554, PubMed 24362313

Bosly A, Grigg A, Holte H, Gisselbrecht C, Radford J, Rossi A, Lopez-Guillermo A, Trneny M, Sebban C, Hagberg H, Leal da Costa F, Colombat P, Bron D, Coiffier B (2013)
A randomized study of interferon α-2b versus no treatment as consolidation after high dose therapy and autologous stem cell transplantation for patients with relapsed lymphoma
Oncologist, 18 (11), 1189
DOI 10.1634/theoncologist.2013-0223, PubMed 24105750

Brodtkorb M, Lingjærde OC, Huse K, Trøen G, Hystad M, Hilden VI, Myklebust JH, Leich E, Rosenwald A, Delabie J, Holte H, Smeland EB (2013)
Whole-genome integrative analysis reveals expression signatures predicting transformation in follicular lymphoma
Blood, 123 (7), 1051-4
DOI 10.1182/blood-2013-07-512392, PubMed 24357726

Dörffel W, Rühl U, Lüders H, Claviez A, Albrecht M, Bökkerink J, Holte H, Karlen J, Mann G, Marciniak H, Niggli F, Schmiegelow K, Schwarze EW, Pötter R, Wickmann L, Schellong G (2013)
Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95
J Clin Oncol, 31 (12), 1562-8
DOI 10.1200/JCO.2012.45.3266, PubMed 23509321

Fiskvik I, Aamot HV, Delabie J, Smeland EB, Stokke T, Heim S, Holte H (2013)
Karyotyping of diffuse large B-cell lymphomas: loss of 17p is associated with poor patient outcome
Eur J Haematol, 91 (4), 332-8
DOI 10.1111/ejh.12171, PubMed 23859481

Hagtvedt T, Aaløkken TM, Smith HJ, Graff BA, Holte H, Kolbenstvedt A (2013)
Enhancement characteristics of retroperitoneal lymphomatous lymph nodes
Acta Radiol, 54 (3), 333-9
DOI 10.1258/ar.2012.120679, PubMed 23446747

Smeland KB, Kiserud CE, Lauritzsen GF, Blystad AK, Fagerli UM, Fluge Ø, Fosså A, Hammerstrøm J, Kolstad A, Loge JH, Maisenhølder M, Østenstad B, Kvaløy S, Holte H (2013)
High-dose therapy with autologous stem cell support for lymphoma in Norway 1987-2008
Tidsskr Nor Laegeforen, 133 (16), 1704-9
DOI 10.4045/tidsskr.13.0243, PubMed 24005706

Smeland KB, Kiserud CE, Lauritzsen GF, Fosså A, Hammerstrøm J, Jetne V, Kolstad A, Kvalheim G, Loge JH, Løkeland T, Tangen JM, Holte H, Kvaløy S (2013)
High-dose therapy with autologous stem cell support for lymphoma--from experimental to standard treatment
Tidsskr Nor Laegeforen, 133 (16), 1735-9
DOI 10.4045/tidsskr.13.0319, PubMed 24005713

Wahlin BE, Sundström C, Sander B, Christensson B, Jeppsson-Ahlberg Å, Hjalmarsson E, Holte H, Østenstad B, Brown PD, Smeland EB, Kimby E (2013)
Higher World Health Organization grades of follicular lymphoma correlate with better outcome in two Nordic Lymphoma Group trials of rituximab without chemotherapy
Leuk Lymphoma, 55 (2), 288-95
DOI 10.3109/10428194.2013.802778, PubMed 23662992

Yri OE, Ekstrøm PO, Hilden V, Gaudernack G, Liestøl K, Smeland EB, Holte H (2013)
Influence of polymorphisms in genes encoding immunoregulatory proteins and metabolizing enzymes on susceptibility and outcome in patients with diffuse large B-cell lymphoma treated with rituximab
Leuk Lymphoma, 54 (10), 2205-14
DOI 10.3109/10428194.2013.774392, PubMed 23391141

Publications 2012

d'Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, Holte H, Österborg A, Merup M, Brown P, Kuittinen O, Erlanson M, Østenstad B, Fagerli UM, Gadeberg OV, Sundström C, Delabie J, Ralfkiaer E, Vornanen M, Toldbod HE (2012)
Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01
J Clin Oncol, 30 (25), 3093-9
DOI 10.1200/JCO.2011.40.2719, PubMed 22851556

Fløisand Y, Brinch L, Gedde-Dahl T, Tjønnfjord GE, Dybedal I, Holte H, Heldal D, Torfoss D, Aurlien E, Lauritzsen GF, Fosså A, Lehne G, Baggerød E, Kvalheim G, Egeland T, Bishop MR, Fowler DH, Kolstad A (2012)
Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantation
Bone Marrow Transplant, 47 (12), 1552-7
DOI 10.1038/bmt.2012.63, PubMed 22522568

Holte H, Leppä S, Björkholm M, Fluge O, Jyrkkiö S, Delabie J, Sundström C, Karjalainen-Lindsberg ML, Erlanson M, Kolstad A, Fosså A, Ostenstad B, Löfvenberg E, Nordström M, Janes R, Pedersen LM, Anderson H, Jerkeman M, Eriksson M (2012)
Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study
Ann Oncol, 24 (5), 1385-92
DOI 10.1093/annonc/mds621, PubMed 23247661

Mitrovic Z, Perry AM, Suzumiya J, Armitage JO, Au WY, Coiffier B, Holte H, Jaffe ES, Monserrat E, Rajan SK, Savage KJ, Tobinai K, Vose JM, Weisenburger DD (2012)
The prognostic significance of lymphopenia in peripheral T-cell and natural killer/T-cell lymphomas: a study of 826 cases from the International Peripheral T-cell Lymphoma Project
Am J Hematol, 87 (8), 790-4
DOI 10.1002/ajh.23205, PubMed 22488678

Riihijärvi S, Nurmi H, Holte H, Björkholm M, Fluge O, Pedersen LM, Rydström K, Jerkeman M, Eriksson M, Leppä S (2012)
High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy
Eur J Haematol, 89 (5), 395-402
DOI 10.1111/ejh.12005, PubMed 22882209

Wahlin BE, Sander B, Christensson B, Ostenstad B, Holte H, Brown PD, Sundström C, Kimby E (2012)
Entourage: the immune microenvironment following follicular lymphoma
Blood Cancer J, 2 (1), e52
DOI 10.1038/bcj.2011.53, PubMed 22829236

Yri OE, Ekstrøm PO, Hilden V, Gaudernack G, Liestøl K, Smeland EB, Holte H (2012)
Polymorphisms in genes encoding interleukin-10 and drug metabolizing enzymes GSTP1, GSTT1, GSTA1 and UGT1A1 influence risk and outcome in Hodgkin lymphoma
Leuk Lymphoma, 53 (10), 1934-44
DOI 10.3109/10428194.2012.682307, PubMed 22475179

Publications 2011

Delabie J, Holte H, Vose JM, Ullrich F, Jaffe ES, Savage KJ, Connors JM, Rimsza L, Harris NL, Müller-Hermelink K, Rüdiger T, Coiffier B, Gascoyne RD, Berger F, Tobinai K, Au WY, Liang R, Montserrat E, Hochberg EP, Pileri S, Federico M, Nathwani B, Armitage JO, Weisenburger DD (2011)
Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project
Blood, 118 (1), 148-55
DOI 10.1182/blood-2011-02-335216, PubMed 21566094

Eide MB, Lauritzsen GF, Kvalheim G, Kolstad A, Fagerli UM, Maisenhölder M, Østenstad B, Fluge Ø, Delabie J, Aarset H, Liestøl K, Holte H (2011)
High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study
Br J Haematol, 152 (5), 600-10
DOI 10.1111/j.1365-2141.2010.08519.x, PubMed 21241276

Fosså A, Fiskvik IH, Kolstad A, Lauritzsen GF, Aurlien E, Blystad AK, Hole KH, Ikonomou IM, Holte H (2011)
Two escalated followed by six standard BEACOPP in advanced-stage high-risk classical Hodgkin lymphoma: high cure rates but increased risk of aseptic osteonecrosis
Ann Oncol, 23 (5), 1254-1259
DOI 10.1093/annonc/mdr385, PubMed 21926399

Grotmol T, Bray F, Holte H, Haugen M, Kunz L, Tretli S, Aalen OO, Moger TA (2011)
Frailty modeling of the bimodal age-incidence of Hodgkin lymphoma in the Nordic countries
Cancer Epidemiol Biomarkers Prev, 20 (7), 1350-7
DOI 10.1158/1055-9965.EPI-10-1014, PubMed 21558495

Hagtvedt T, Aaløkken TM, Smith HJ, Graff BA, Holte H, Kolbenstvedt A (2011)
Enhancement characteristics of lymphomatous lymph nodes of the mediastinum
Acta Radiol, 52 (10), 1113-8
DOI 10.1258/ar.2011.110265, PubMed 22052959

Torfoss D, Høiby EA, Holte H, Kvaløy S (2011)
The Norwegian experience with penicillin G plus an aminoglycoside as initial empiric therapy in febrile neutropenia; a review
Acta Oncol, 51 (4), 433-40
DOI 10.3109/0284186X.2011.633931, PubMed 22175253

Torfoss D, Sandstad B, Mollnes TE, Høiby EA, Holte H, Bjerner J, Bjøro T, Gaudernack G, Kvalheim G, Kvaløy S (2011)
The mild inflammatory response in febrile neutropenic lymphoma patients with low risk of complications is more pronounced in patients receiving tobramycin once daily compared with three times daily
Scand J Immunol, 74 (6), 632-9
DOI 10.1111/j.1365-3083.2011.02618.x, PubMed 21883353

Wahlin BE, Sundström C, Holte H, Hagberg H, Erlanson M, Nilsson-Ehle H, Lindén O, Nordström M, Ostenstad B, Geisler CH, Brown Pde N, Lehtinen T, Maisenhölder M, Tierens AM, Sander B, Christensson B, Kimby E (2011)
T cells in tumors and blood predict outcome in follicular lymphoma treated with rituximab
Clin Cancer Res, 17 (12), 4136-44
DOI 10.1158/1078-0432.CCR-11-0264, PubMed 21518780

Wahlin BE, Yri OE, Kimby E, Holte H, Delabie J, Smeland EB, Sundström C, Christensson B, Sander B (2011)
Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times
Br J Haematol, 156 (2), 225-33
DOI 10.1111/j.1365-2141.2011.08942.x, PubMed 22126847

Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA, Rüdiger T, Pileri S, Nakamura S, Nathwani B, Campo E, Berger F, Coiffier B, Kim WS, Holte H, Federico M, Au WY, Tobinai K, Armitage JO, Vose JM, International Peripheral T-cell Lymphoma Project (2011)
Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project
Blood, 117 (12), 3402-8
DOI 10.1182/blood-2010-09-310342, PubMed 21270441

Publications 2010

Eide MB, Liestøl K, Lingjaerde OC, Hystad ME, Kresse SH, Meza-Zepeda L, Myklebost O, Trøen G, Aamot HV, Holte H, Smeland EB, Delabie J (2010)
Genomic alterations reveal potential for higher grade transformation in follicular lymphoma and confirm parallel evolution of tumor cell clones
Blood, 116 (9), 1489-97
DOI 10.1182/blood-2010-03-272278, PubMed 20505157

Hagtvedt T, Aaløkken TM, Smith HJ, Graff BA, Holte H, Kolbenstvedt A (2010)
Enhancement characteristics of lymphomatous lymph nodes of the neck
Acta Radiol, 51 (5), 555-62
DOI 10.3109/02841851003698198, PubMed 20429760

Kiserud CE, Loge JH, Fosså A, Holte H, Cvancarova M, Fosså SD (2010)
Mortality is persistently increased in Hodgkin's lymphoma survivors
Eur J Cancer, 46 (9), 1632-9
DOI 10.1016/j.ejca.2010.02.010, PubMed 20219350

Linch DC, Yung L, Smith P, Maclennan K, Jack A, Hancock B, Cunningham D, Hoskin P, Qian W, Holte H, Boesen AM, Grigg A, Browett P, Trneny M (2010)
Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL
Br J Haematol, 149 (2), 237-43
DOI 10.1111/j.1365-2141.2010.08081.x, PubMed 20201949

Ruland CM, Holte HH, Røislien J, Heaven C, Hamilton GA, Kristiansen J, Sandbaek H, Kvaløy SO, Hasund L, Ellison MC (2010)
Effects of a computer-supported interactive tailored patient assessment tool on patient care, symptom distress, and patients' need for symptom management support: a randomized clinical trial
J Am Med Inform Assoc, 17 (4), 403-10
DOI 10.1136/jamia.2010.005660, PubMed 20595307

Tauro S, Cochrane L, Lauritzsen GF, Baker L, Delabie J, Roberts C, Mahendra P, Holte H (2010)
Dose-intensified treatment of Burkitt lymphoma and B-cell lymphoma unclassifiable, (with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma) in young adults (<50 years): a comparison of two adapted BFM protocols
Am J Hematol, 85 (4), 261-3
DOI 10.1002/ajh.21648, PubMed 20201088

Tierens AM, Holte H, Warsame A, Ikonomou IM, Wang J, Chan WC, Delabie J (2010)
Low levels of monoclonal small B cells in the bone marrow of patients with diffuse large B-cell lymphoma of activated B-cell type but not of germinal center B-cell type
Haematologica, 95 (8), 1334-41
DOI 10.3324/haematol.2009.014100, PubMed 20145271

van Oers MH, Tönnissen E, Van Glabbeke M, Giurgea L, Jansen JH, Klasa R, Marcus RE, Wolf M, Kimby E, Vranovsky A, Holte H, Hagenbeek A, van der Reijden BA (2010)
BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study
J Clin Oncol, 28 (13), 2246-52
DOI 10.1200/JCO.2009.25.0852, PubMed 20368567

van Oers MH, Van Glabbeke M, Giurgea L, Klasa R, Marcus RE, Wolf M, Kimby E, van t Veer M, Vranovsky A, Holte H, Hagenbeek A (2010)
Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study
J Clin Oncol, 28 (17), 2853-8
DOI 10.1200/JCO.2009.26.5827, PubMed 20439641

van Oers MHJ, Tonnissen E, van Glabbeke M, Giurgea L, Jansen JH, Klasa R, Marcus RE, Wolf M, Kimby E, Vranovsky A, Holte H, Hagenbeek A, van der Reijden BA (2010)
Prognostic Significance of Molecular Remission in Follicular Lymphoma Reply
J. Clin. Oncol., 28 (30), E614
DOI 10.1200/JCO.2010.30.8353

Publications 2009

Holte H, Kvaløy S, Delabie J, Trøen G, Smeland EB (2009)
[Molecular diagnosis of malignant lymphomas]
Tidsskr Nor Laegeforen, 129 (22), 2352-6
DOI 10.4045/tidsskr.09.0704, PubMed 19935935

Kelly JL, Toothaker SR, Ciminello L, Hoelzer D, Holte H, LaCasce AS, Mead G, Thomas D, Van Imhoff GW, Kahl BS, Cheson BD, Magrath IT, Fisher RI, Friedberg JW (2009)
Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens
Clin Lymphoma Myeloma, 9 (4), 307-10
DOI 10.3816/CLM.2009.n.060, PubMed 19717381

Kiserud CE, Fosså A, Bjøro T, Holte H, Cvancarova M, Fosså SD (2009)
Gonadal function in male patients after treatment for malignant lymphomas, with emphasis on chemotherapy
Br J Cancer, 100 (3), 455-63
DOI 10.1038/sj.bjc.6604892, PubMed 19156143

Kiserud CE, Schover LR, Dahl AA, Fosså A, Bjøro T, Loge JH, Holte H, Yuan Y, Fosså SD (2009)
Do male lymphoma survivors have impaired sexual function?
J Clin Oncol, 27 (35), 6019-26
DOI 10.1200/JCO.2009.23.2280, PubMed 19858388

O'Shea D, O'Riain C, Gupta M, Waters R, Yang Y, Wrench D, Gribben J, Rosenwald A, Ott G, Rimsza LM, Holte H, Cazier JB, Johnson NA, Campo E, Chan WC, Gascoyne RD, Young BD, Staudt LM, Lister TA, Fitzgibbon J (2009)
Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation
Blood, 113 (10), 2298-301
DOI 10.1182/blood-2008-08-174953, PubMed 19141865

Wethal T, Lund MB, Edvardsen T, Fosså SD, Pripp AH, Holte H, Kjekshus J, Fosså A (2009)
Valvular dysfunction and left ventricular changes in Hodgkin's lymphoma survivors. A longitudinal study
Br J Cancer, 101 (4), 575-81
DOI 10.1038/sj.bjc.6605191, PubMed 19623176

Publications 2008

Kimby E, Jurlander J, Geisler C, Hagberg H, Holte H, Lehtinen T, Ostenstad B, Hansen M, Osterborg A, Lindén O, Sundström C, Nordic Lymphoma Group (2008)
Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group
Leuk Lymphoma, 49 (1), 102-12
DOI 10.1080/10428190701704647, PubMed 18203019

Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, Vose J, Bast M, Fu K, Weisenburger DD, Greiner TC, Armitage JO, Kyle A, May L, Gascoyne RD, Connors JM, Troen G, Holte H, Kvaloy S, Dierickx D, Verhoef G et al. (2008)
Stromal gene signatures in large-B-cell lymphomas
N Engl J Med, 359 (22), 2313-23
DOI 10.1056/NEJMoa0802885, PubMed 19038878

Torfoss D, Høiby EA, Holte H, Kvaløy S (2008)
[Penicillin and aminoglycoside in febrile neutropenia]
Tidsskr Nor Laegeforen, 128 (23), 2738-40
PubMed 19079423

Publications 2007

Björkholm M, Hagberg H, Holte H, Kvaloy S, Teerenhovi L, Anderson H, Cavallin-Ståhl E, Myhre J, Pertovaara H, Ost A, Nilsson B, Osby E (2007)
Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up
Ann Oncol, 18 (6), 1085-9
DOI 10.1093/annonc/mdm073, PubMed 17363838

Kiserud CE, Fosså A, Holte H, Fosså SD (2007)
Post-treatment parenthood in Hodgkin's lymphoma survivors
Br J Cancer, 96 (9), 1442-9
DOI 10.1038/sj.bjc.6603711, PubMed 17406362

Kolstad A, Holte H, Fosså A, Lauritzsen GF, Gaustad P, Torfoss D (2007)
Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen
Haematologica, 92 (1), 139-40
DOI 10.3324/haematol.10564, PubMed 17229653

Kolstad A, Nome O, Delabie J, Lauritzsen GF, Fossa A, Holte H (2007)
Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphoma
Leuk Lymphoma, 48 (3), 570-6
DOI 10.1080/10428190601126610, PubMed 17454601

Oldervoll LM, Loge JH, Kaasa S, Lydersen S, Hjermstad MJ, Thorsen L, Holte H, Jacobsen AB, Fosså SD (2007)
Physical activity in Hodgkin's lymphoma survivors with and without chronic fatigue compared with the general population - a cross-sectional study
BMC Cancer, 7, 210
DOI 10.1186/1471-2407-7-210, PubMed 17997822

Torfoss D, Høiby EA, Tangen JM, Holte H, Bø K, Meyer P, Grøttum K, Weyde K, Lauritzsen GF, Sandstad B, Jacobsen AB, Olsen H, Kvaløy S (2007)
Tobramycin once versus three times daily, given with penicillin G, to febrile neutropenic cancer patients in Norway: a prospective, randomized, multicentre trial
J Antimicrob Chemother, 59 (4), 711-7
DOI 10.1093/jac/dkm003, PubMed 17327294

Wiestner A, Tehrani M, Chiorazzi M, Wright G, Gibellini F, Nakayama K, Liu H, Rosenwald A, Muller-Hermelink HK, Ott G, Chan WC, Greiner TC, Weisenburger DD, Vose J, Armitage JO, Gascoyne RD, Connors JM, Campo E, Montserrat E, Bosch F, Smeland EB, Kvaloy S, Holte H, Delabie J, Fisher RI et al. (2007)
Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival
Blood, 109 (11), 4599-606
DOI 10.1182/blood-2006-08-039859, PubMed 17299095

Wilking N, Lidbrink E, Wiklund T, Erikstein B, Lindman H, Malmström P, Kellokumpu-Lehtinen P, Bengtsson NO, Söderlund G, Anker G, Wist E, Ottosson S, Salminen E, Ljungman P, Holte H, Nilsson J, Blomqvist C, Bergh J (2007)
Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy
Ann Oncol, 18 (4), 694-700
DOI 10.1093/annonc/mdl488, PubMed 17301072

Aamot HV, Torlakovic EE, Eide MB, Holte H, Heim S (2007)
Non-Hodgkin lymphoma with t(14;18): clonal evolution patterns and cytogenetic-pathologic-clinical correlations
J Cancer Res Clin Oncol, 133 (7), 455-70
DOI 10.1007/s00432-006-0188-3, PubMed 17235551

Publications 2006

Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, Greiner TC, Weisenburger DD, Rosenwald A, Ott G, Müller-Hermelink HK, Gascoyne RD, Delabie J, Rimsza LM, Braziel RM, Grogan TM, Campo E, Jaffe ES, Dave BJ, Sanger W, Bast M, Vose JM, Armitage JO, Connors JM, Smeland EB et al. (2006)
Molecular diagnosis of Burkitt's lymphoma
N Engl J Med, 354 (23), 2431-42
DOI 10.1056/NEJMoa055759, PubMed 16760443

Haukvik UK, Dieset I, Bjøro T, Holte H, Fosså SD (2006)
Treatment-related premature ovarian failure as a long-term complication after Hodgkin's lymphoma
Ann Oncol, 17 (9), 1428-33
DOI 10.1093/annonc/mdl149, PubMed 16831852

Hjermstad MJ, Hollender A, Warloe T, Karlsen KO, Ikonomo I, Kvaloy S, Nome O, Holte H (2006)
Quality of life after total or partial gastrectomy for primary gastric lymphoma
Acta Oncol, 45 (2), 202-9
DOI 10.1080/02841860500492067, PubMed 16546867

Hollender A, Bjøro T, Otto Karlsen K, Kvaloy SO, Nome O, Holte H (2006)
Vitamin D deficiency in patients operated on for gastric lymphoma
Scand J Gastroenterol, 41 (6), 673-81
DOI 10.1080/00365520500356510, PubMed 16716965

Sivertsen EA, Galteland E, Mu D, Holte H, Meza-Zepeda L, Myklebost O, Patzke S, Smeland EB, Stokke T (2006)
Gain of chromosome 6p is an infrequent cause of increased PIM1 expression in B-cell non-Hodgkin's lymphomas
Leukemia, 20 (3), 539-42
DOI 10.1038/sj.leu.2404094, PubMed 16437153

van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, Jack A, Van't Veer M, Vranovsky A, Holte H, van Glabbeke M, Teodorovic I, Rozewicz C, Hagenbeek A (2006)
Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial
Blood, 108 (10), 3295-301
DOI 10.1182/blood-2006-05-021113, PubMed 16873669

Publications 2005

Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V, Burek C, Ott G, Puig X, Yang L, Lopez-Guillermo A, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Gascoyne RD, Connors JM, Grogan TM, Braziel R, Fisher RI, Smeland EB, Kvaloy S, Holte H, Delabie J, Simon R et al. (2005)
Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction
Blood, 106 (9), 3183-90
DOI 10.1182/blood-2005-04-1399, PubMed 16046532

Fosså SD, Holte H, Holmen MM, Bjøro T, Langmark F, Hess SL, Kvaløy S (2005)
[Long-term effects after mantle field radiotherapy for Hodgkin's lymphoma]
Tidsskr Nor Laegeforen, 125 (1), 41-4
PubMed 15643464

Hjermstad MJ, Fosså SD, Oldervoll L, Holte H, Jacobsen AB, Loge JH (2005)
Fatigue in long-term Hodgkin's Disease survivors: a follow-up study
J Clin Oncol, 23 (27), 6587-95
DOI 10.1200/JCO.2005.09.936, PubMed 16170166

Hjermstad MJ, Oldervoll L, Fosså SD, Holte H, Jacobsen AB, Loge JH (2005)
Quality of life in long-term Hodgkin's disease survivors with chronic fatigue
Eur J Cancer, 42 (3), 327-33
DOI 10.1016/j.ejca.2005.09.028, PubMed 16377179

Aamot HV, Micci F, Holte H, Delabie J, Heim S (2005)
G-banding and molecular cytogenetic analyses of marginal zone lymphoma
Br J Haematol, 130 (6), 890-901
DOI 10.1111/j.1365-2141.2005.05706.x, PubMed 16156859

Publications 2004

Blystad AK, Delabie J, Kvaløy S, Holte H, Vålerhaugen H, Ikonomou I, Kvalheim G (2004)
Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy
Br J Haematol, 125 (5), 605-12
DOI 10.1111/j.1365-2141.2004.04951.x, PubMed 15147376

Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM, Rimsza LM, Grogan TM, Miller TP, LeBlanc M, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Connors JM, Lansdorp PM, Ouyang Q, Lister TA et al. (2004)
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells
N Engl J Med, 351 (21), 2159-69
DOI 10.1056/NEJMoa041869, PubMed 15548776

Hjermstad MJ, Knobel H, Brinch L, Fayers PM, Loge JH, Holte H, Kaasa S (2004)
A prospective study of health-related quality of life, fatigue, anxiety and depression 3-5 years after stem cell transplantation
Bone Marrow Transplant, 34 (3), 257-66
DOI 10.1038/sj.bmt.1704561, PubMed 15170167

Jerkeman M, Leppä S, Kvaløy S, Holte H (2004)
ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma--the Nordic Lymphoma Group experience
Eur J Haematol, 73 (3), 179-82
DOI 10.1111/j.1600-0609.2004.00294.x, PubMed 15287915

Kolstad A, Risberg T, Bremnes Y, Wilsgaard T, Holte H, Klepp O, Mella O, Wist E (2004)
Use of complementary and alternative therapies: a national multicentre study of oncology health professionals in Norway
Support Care Cancer, 12 (5), 312-8
DOI 10.1007/s00520-004-0590-9, PubMed 14767750

Nermoen I, Foss A, Holte H, Mathisen Ø, Brekke IB, Line PD, Bergan A (2004)
[Surgical treatment of hormone-producing adrenocortical carcinoma with liver metastases]
Tidsskr Nor Laegeforen, 124 (23), 3061-3
PubMed 15586188

Risberg T, Bremnes Y, Kolstad A, Holte H, Wist E, Mella O, Klepp O (2004)
[Should complementary therapies be offered in hospitals?]
Tidsskr Nor Laegeforen, 124 (23), 3078-80
PubMed 15586193

Risberg T, Kolstad A, Bremnes Y, Holte H, Wist EA, Mella O, Klepp O, Wilsgaard T, Cassileth BR (2004)
Knowledge of and attitudes toward complementary and alternative therapies; a national multicentre study of oncology professionals in Norway
Eur J Cancer, 40 (4), 529-35
DOI 10.1016/j.ejca.2003.11.011, PubMed 14962719

Smeland S, Blystad AK, Kvaløy SO, Ikonomou IM, Delabie J, Kvalheim G, Hammerstrøm J, Lauritzsen GF, Holte H (2004)
Treatment of Burkitt's/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens
Ann Oncol, 15 (7), 1072-8
DOI 10.1093/annonc/mdh262, PubMed 15205201

Publications 2003

Osby E, Hagberg H, Kvaløy S, Teerenhovi L, Anderson H, Cavallin-Stahl E, Holte H, Myhre J, Pertovaara H, Björkholm M, Nordic Lymphoma Group (2003)
CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial
Blood, 101 (10), 3840-8
DOI 10.1182/blood-2002-10-3238, PubMed 12531794

Risberg T, Kolstad A, Wist EA, Holte H, Mella O, Klepp O (2003)
[Should alternative therapists treat cancer--what is the opinion of oncology health personnel?]
Tidsskr Nor Laegeforen, 123 (21), 3059-61
PubMed 14618177

Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD, Chan WC, Zhao T, Haioun C, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Campo E, Montserrat E, Lopez-Guillermo A, Ott G, Muller-Hermelink HK, Connors JM, Braziel R et al. (2003)
Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma
J Exp Med, 198 (6), 851-62
DOI 10.1084/jem.20031074, PubMed 12975453

Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, Gascoyne RD, Grogan TM, Muller-Hermelink HK, Smeland EB, Chiorazzi M, Giltnane JM, Hurt EM, Zhao H, Averett L, Henrickson S, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, Montserrat E, Bosch F, Greiner TC et al. (2003)
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma
Cancer Cell, 3 (2), 185-97
DOI 10.1016/s1535-6108(03)00028-x, PubMed 12620412

Publications 2002

Foss Abrahamsen A, Andersen A, Nome O, Jacobsen AB, Holte H, Foss Abrahamsen J, Kvaløy S (2002)
Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time
Ann Oncol, 13 (11), 1786-91
DOI 10.1093/annonc/mdf289, PubMed 12419752

Hollender A, Kvaloy S, Nome O, Skovlund E, Lote K, Holte H (2002)
Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model
Ann Oncol, 13 (7), 1099-107
DOI 10.1093/annonc/mdf175, PubMed 12176790

Holte H, Smeland S, Blystad AK, Kvaløy S, Hammerstrøm J, Tjønnfjord GE (2002)
[Intensive chemotherapy in Burkitt's lymphoma and aggressive non-Hodgkin's lymphoma]
Tidsskr Nor Laegeforen, 122 (4), 364-9
PubMed 11915663

Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ et al. (2002)
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
N Engl J Med, 346 (25), 1937-47
DOI 10.1056/NEJMoa012914, PubMed 12075054

Aamot H, Micci F, Holte H, Delabie J, Heim S (2002)
M-FISH cytogenetic analysis of non-Hodgkin lymphomas with t(14;18)(q32;q21) and add(1)(p36) as a secondary abnormality shows that the extra material often comes from chromosome arm 17q
Leuk Lymphoma, 43 (5), 1051-6
DOI 10.1080/10428190290021551, PubMed 12148885

Publications 2001

Aurlien E, Holte H, Kvaloy S, Jakobsen E, Rusten LS, Kvalheim G (2001)
Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients
Eur. J. Haematol., 66 64, 14-20

Aurlien E, Holte H, Kvaløy S, Jakobsen E, Rusten LS, Kvalheim G (2001)
Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients
Eur J Haematol Suppl, 64, 14-20
PubMed 11486395

Blystad AK, Enblad G, Kvaløy S, Berglund A, Delabie J, Holte H, Carlson K, Kvalheim G, Bengtsson M, Hagberg H (2001)
High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas
Bone Marrow Transplant, 27 (7), 711-6
DOI 10.1038/sj.bmt.1702867, PubMed 11360110

Blystad AK, Holte H, Kvaløy S, Smeland E, Delabie J, Kvalheim G (2001)
High-dose therapy in patients with Hodgkin's disease: the use of selected CD34(+) cells is as safe as unmanipulated peripheral blood progenitor cells
Bone Marrow Transplant, 28 (9), 849-57
DOI 10.1038/sj.bmt.1703244, PubMed 11781645

Blystad AK, Torlakovic E, Holte H, Kvaløy S, Lenschow E, Kvalheim G (2001)
CD34(+) cell enrichment depletes atypical CD30(+) cells from PBPC grafts in patients with HD
Cytotherapy, 3 (4), 295-305
DOI 10.1080/146532401317070934, PubMed 12171718

Hall KS, Wiklund T, Erikstein B, Holte H, Kvalheim G, Sommer HH, Andersen A, Skovlund E, Bergh J, Hall C (2001)
Effects of dose-intensive chemotherapy and radiotherapy on serum n-terminal proatrial natriuretic peptide in high-risk breast cancer patients
Breast Cancer Res Treat, 67 (3), 235-44
DOI 10.1023/a:1017946315032, PubMed 11561769

Holte HH, Tambs K, Bjerkedal T (2001)
Becoming a disability pensioner with rheumatoid arthritis in Norway 1971-1990
J Rheumatol, 28 (1), 54-61
PubMed 11196543

Nordøy T, Husebekk A, Aaberge IS, Jenum PA, Samdal HH, Flugsrud LB, Kristoffersen AC, Holte H, Kvaløy S, Kolstad A (2001)
Humoral immunity to viral and bacterial antigens in lymphoma patients 4-10 years after high-dose therapy with ABMT. Serological responses to revaccinations according to EBMT guidelines
Bone Marrow Transplant, 28 (7), 681-7
DOI 10.1038/sj.bmt.1703228, PubMed 11704791

Stokke T, DeAngelis P, Smedshammer L, Galteland E, Steen HB, Smeland EB, Delabie J, Holte H (2001)
Loss of chromosome 11q21-23.1 and 17p and gain of chromosome 6p are independent prognostic indicators in B-cell non-Hodgkin's lymphoma
Br J Cancer, 85 (12), 1900-13
DOI 10.1054/bjoc.2001.2164, PubMed 11747333

Sweetenham JW, Santini G, Qian W, Guelfi M, Schmitz N, Simnett S, Nagler A, Holte H, Kvaloy S, Bruzzi P, Goldstone AH (2001)
High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group
J Clin Oncol, 19 (11), 2927-36
DOI 10.1200/JCO.2001.19.11.2927, PubMed 11387366

Publications 2000

Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmström P, Kellokumpu-Lehtinen P, Bengtsson NO, Söderlund G, Anker G, Wist E, Ottosson S, Salminen E, Ljungman P, Holte H, Nilsson J, Blomqvist C, Wilking N (2000)
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study
Lancet, 356 (9239), 1384-91
DOI 10.1016/s0140-6736(00)02841-5, PubMed 11052580

Hagen KB, Holte HH, Tambs K, Bjerkedal T (2000)
Socioeconomic factors and disability retirement from back pain: a 1983-1993 population-based prospective study in Norway
Spine (Phila Pa 1976), 25 (19), 2480-7
DOI 10.1097/00007632-200010010-00010, PubMed 11013500

Hollender A, Kvaloy S, Lote K, Nome O, Holte H (2000)
Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis
Eur J Cancer, 36 (14), 1762-8
DOI 10.1016/s0959-8049(00)00171-4, PubMed 10974623

Holte HH, Tambs K, Bjerkedal T (2000)
Manual work as predictor for disability pensioning with osteoarthritis among the employed in Norway 1971-1990
Int J Epidemiol, 29 (3), 487-94
DOI 10.1093/ije/29.3.487, PubMed 10869321

Lote K, Holte H, Kvaloy S (2000)
Testicular lymphoma is associated with a high risk of extranodal recurrence
Cancer, 89 (3), 713-4
PubMed 10931479

Lote K, Holte H, Nome O, Langholm R, Kvaløy S (2000)
Stage I high-grade non-Hodgkin's lymphoma
Acta Oncol, 39 (7), 865-72
DOI 10.1080/028418600750063631, PubMed 11145446

Stokke T, Galteland E, Holte H, Smedshammer L, Suo Z, Smeland EB, Børresen-Dale AL, DeAngelis P, Steen HB (2000)
Oncogenic aberrations in the p53 pathway are associated with a high S phase fraction and poor patient survival in B-cell Non-Hodgkin's lymphoma
Int J Cancer, 89 (4), 313-24
DOI 10.1002/1097-0215(20000720)89:4<313::aid-ijc1>3.0.co;2-d, PubMed 10956404

Publications 1999

Abrahamsen AF, Loge JH, Hannisdal E, Nome O, Lund MB, Holte H, Kvaløy S (1999)
Late medical sequelae after therapy for supradiaphragmatic Hodgkin's disease
Acta Oncol, 38 (4), 511-5
DOI 10.1080/028418699432068, PubMed 10418720

Andersen A, Holte H, Slørdal L (1999)
Pharmacokinetics and metabolism of doxorubicin after short-term infusions in lymphoma patients
Cancer Chemother Pharmacol, 44 (5), 422-6
DOI 10.1007/s002800050999, PubMed 10501917

Blystad A, Kvalheim G, Torlakovic E, Holte H, Jacobsen E, Beiske K, Vâlerhaugen H, Lenschow E, Kvaloy S (1999)
High-dose therapy supported with immunomagnetic purged autologous bone marrow in high-grade B cell non-Hodgkin's lymphoma
Bone Marrow Transplant, 24 (8), 865-72
DOI 10.1038/sj.bmt.1701990, PubMed 10516698

Galteland E, Holte H, Stokke T (1999)
c-MYC, RB-1, TP53, and centromere 8 and 17 copy number in B-cell non-Hodgkin's lymphomas assessed by dual-color fluorescence in situ hybridization
Cytometry, 38 (2), 53-60
DOI 10.1002/(sici)1097-0320(19990415)38:2<53::aid-cyto2>3.3.co;2-s, PubMed 10323217

Hjermstad M, Holte H, Evensen S, Fayers P, Kaasa S (1999)
Do patients who are treated with stem cell transplantation have a health-related quality of life comparable to the general population after 1 year?
Bone Marrow Transplant, 24 (8), 911-8
DOI 10.1038/sj.bmt.1701998, PubMed 10516705

Holte H, Suo Z, Smeland EB, Kvaløy S, Langholm R, Stokke T (1999)
Prognostic value of lymphoma-specific S-phase fraction compared with that of other cell proliferation markers
Acta Oncol, 38 (4), 495-503
DOI 10.1080/028418699432040, PubMed 10418718

Lindman H, Wiklund T, Holte H, Ljungman P, Blomqvist C, Kvalheim G, Bengtsson M, Höglund M, Wilking N, Bergh J (1999)
FEC mobilized stem cells for high-dose therapy in breast cancer patients. SB6 9401 Study Group
Acta Oncol, 38 (2), 239-45
DOI 10.1080/028418699431672, PubMed 10227447

Nordøy T, Kolstad A, Endresen P, Holte H, Kvaløy S, Kvalheim G, Husebekk A (1999)
Persistent changes in the immune system 4-10 years after ABMT
Bone Marrow Transplant, 24 (8), 873-8
DOI 10.1038/sj.bmt.1702006, PubMed 10516699

Publications 1998

Abrahamsen AF, Loge JH, Hannisdal E, Holte H, Kvaløy S (1998)
Socio-medical situation for long-term survivors of Hodgkin's disease: a survey of 459 patients treated at one institution
Eur J Cancer, 34 (12), 1865-70
DOI 10.1016/s0959-8049(98)00269-x, PubMed 10023307

Aurlien E, Holte H, Pharo A, Kvaløy S, Jakobsen E, Smeland EB, Kvalheim G (1998)
Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma
Bone Marrow Transplant, 21 (9), 873-8
DOI 10.1038/sj.bmt.1701192, PubMed 9613778

Galteland E, Sivertsen EA, Lote K, Holte H, Kvaløy S (1998)
[Primary non-Hodgkin's lymphoma of the brain]
Tidsskr Nor Laegeforen, 118 (29), 4524-6
PubMed 9889638

Stokke T, Holte H, Smedshammer L, Smeland EB, Kaalhus O, Steen HB (1998)
Proliferation and apoptosis in malignant and normal cells in B-cell non-Hodgkin's lymphomas
Br J Cancer, 77 (11), 1832-8
DOI 10.1038/bjc.1998.304, PubMed 9667654

Stokke T, Smeland EB, Kvaløy S, Holte H (1998)
Tumour cell proliferation, but not apoptosis, predicts survival in B-cell non-Hodgkin's lymphomas
Br J Cancer, 77 (11), 1839-41
DOI 10.1038/bjc.1998.305, PubMed 9667655

Publications 1997

Abrahamsen AF, Hoiby EA, Hannisdal E, Jorgensen OG, Holte H, Hasseltvedt V, Host H (1997)
Systemic pneumococcal disease after staging splenectomy for Hodgkin's disease 1969-1980 without pneumococcal vaccine protection: A follow-up study 1994
Eur. J. Haematol., 58 (2), 73-77

Foss Abrahamsen A, Egeland T, Hansen S, Langholm R, Holte H, Kvaløy S (1997)
Hodgkin's disease in a national and hospital population: trends over 20 years
Eur J Cancer, 33 (14), 2380-3
DOI 10.1016/s0959-8049(97)00342-0, PubMed 9616285

Foss Abrahamsen A, Høiby EA, Hannisdal E, Jørgensen OG, Holte H, Hasseltvedt V, Høst H (1997)
Systemic pneumococcal disease after staging splenectomy for Hodgkin's disease 1969-1980 without pneumococcal vaccine protection: a follow-up study 1994
Eur J Haematol, 58 (2), 73-7
DOI 10.1111/j.1600-0609.1997.tb00927.x, PubMed 9111586

Lien HH, Blomlie V, Blystad AK, Holte H, Langholm R, Kvaløy S (1997)
Bone-marrow MR imaging before and after autologous marrow transplantation in lymphoma patients without known bone-marrow involvement
Acta Radiol, 38 (5), 896-902
DOI 10.1080/02841859709172432, PubMed 9332252

Publications 1996

Abrahamsen AF, Hannisdal E, Nome O, Elgio RF, Holte H, Hager B, Langholm R, Kvaløy S (1996)
Prognostic variables and results of salvage treatment in Hodgkin's disease
Acta Oncol, 35 Suppl 8, 67-72
DOI 10.3109/02841869609098522, PubMed 9073050

Abrahamsen AF, Hannisdal E, Nome O, Holte H, Hager B, Langholm R, Kvaløy S (1996)
Clinical stage I and II Hodgkin's disease: long-term results of therapy without laparotomy. Experience at one institution
Ann Oncol, 7 (2), 145-50
DOI 10.1093/oxfordjournals.annonc.a010541, PubMed 8777170

Holte H, Kvaløy SO, Engan T, Evensen SA, Mella O, Tangen JM, Wesenberg F, Wist EA (1996)
[High dose therapy with autologous stem cell support in malignant disorders. Excerpt from the statement by the advisory group of the State Health Services]
Tidsskr Nor Laegeforen, 116 (21), 2577-81
PubMed 8928130

Holte H, Mella O, Wist E, Telhaug R, Hannisdal E, Abrahamsen AF (1996)
ChlVPP is as effective as alternating ChlVPP/ABOD in advanced stage Hodgkin's disease
Acta Oncol, 35 Suppl 8, 73-80
DOI 10.3109/02841869609098523, PubMed 9073051

Kolstad A, Holte H, Kvaløy S, Jakobsen E, Erikstein B, Aurlien E, Kvalheim G, Bøhler PJ, Langholm R (1996)
[High-dose therapy with autologous stem cell support in malignant lymphoma and breast cancer. Experiences with hematopoietic stem cells isolate from blood]
Tidsskr Nor Laegeforen, 116 (21), 2547-51
PubMed 8928122

Kvalheim G, Holte H, Jakobsen E, Kvaloy S (1996)
Immunomagnetic purging of lymphoma cells from autografts
J Hematother, 5 (5), 561-2
DOI 10.1089/scd.1.1996.5.561, PubMed 8938530

Kvalheim G, Pharo A, Holte H, Jakobsen E, Erikstein B, Kvaløy S, Beiske K, Nesland JM, Smeland EB (1996)
[High-dose therapy of cancer with CD34 positive cells as stem cell support]
Tidsskr Nor Laegeforen, 116 (21), 2542-6
PubMed 8928121

Kvalheim G, Wang MY, Pharo A, Holte H, Jacobsen E, Beiske K, Kvaløy S, Smeland E, Funderud S, Fodstad O (1996)
Purging of tumor cells from leukapheresis products: experimental and clinical aspects
J Hematother, 5 (4), 427-36
DOI 10.1089/scd.1.1996.5.427, PubMed 8877718

Lien HH, Holte H (1996)
Fat replacement of Hodgkin disease of bone marrow after chemotherapy: report of three cases
Skeletal Radiol, 25 (7), 671-4
DOI 10.1007/s002560050156, PubMed 8915054

Sletnes KE, Holte H, Halvorsen S, Jakobsen E, Wisløff F, Kvaløy S (1996)
Activation of coagulation and deep vein thrombosis after bone marrow harvesting and insertion of a Hickman-catheter in ABMT patients with malignant lymphoma
Bone Marrow Transplant, 17 (4), 577-81
PubMed 8722358

Waage A, Dahl IM, Evensen SA, Holte H, Lamvik J, Sletnes K, Wisløff F (1996)
[Treatment with growth factors and cytokines in hematologic diseases]
Tidsskr Nor Laegeforen, 116 (12), 1465-9
PubMed 8650635

Publications 1994

Kavløy S, Holte H, Kvalheim G (1994)
[High-dose autologous stem cell support in malignant diseases--an established method, uncertain indication]
Tidsskr Nor Laegeforen, 114 (19), 2240-1
PubMed 7992286

Kvalheim G, Jakobsen E, Holte H, Beiske K, Langholm R, Høiby A, Wang MY, Funderund S, Fodstad O, Smeland E (1994)
Autologous bone marrow transplantation of non-Hodgkin's lymphoma patients with marrow purged using immunomagnetic beads
Prog Clin Biol Res, 389, 133-8
PubMed 7700895

Publications 1993

Erikstein BK, Holte H, Kvaløy S, Andersson KB, Steen HB, Hannisdal E, Smeland EB (1993)
Expression of CD18 (integrin beta 2 chain) correlates with prognosis in malignant B cell lymphomas
Br J Haematol, 83 (3), 392-8
DOI 10.1111/j.1365-2141.1993.tb04662.x, PubMed 8097923

Slørdahl SH, Smeland EB, Holte H, Grønn M, Lie SO, Seip M (1993)
Leukemic blasts with markers of four cell lineages in Down's syndrome ("megakaryoblastic leukemia")
Med Pediatr Oncol, 21 (4), 254-8
DOI 10.1002/mpo.2950210404, PubMed 8469219

Publications 1992

Stokke T, Holte H, Smeland EB, Lie SO, Steen HB (1992)
Differential chromatin structure-dependent binding of 7-aminoactinomycin D in normal and malignant bone marrow hematopoietic cells
Cancer Res, 52 (18), 5007-12
PubMed 1516056

Publications 1991

Alfsen GC, Beiske K, Holte H, Hovig E, Deggerdal A, Sandlie I, Widing E, Slørdahl S, Klepper LK, Sizoo W (1991)
T-cell receptor tau delta +/CD3+4-8-T- cell acute lymphoblastic leukemias: a distinct subgroup of leukemias in children. A report of five cases
Blood, 77 (9), 2023-30
PubMed 1826854

Holte H (1991)
[Resistance to chemotherapeutic agents in the treatment of cancer. Emphasizing the multiresistant phenotype]
Tidsskr Nor Laegeforen, 111 (19), 2423-7
PubMed 1926080

Lømo J, Smeland EB, Stokke T, Holte H, Funderud S, Blomhoff HK (1991)
Differential effects of interferon-gamma and low molecular weight BCGF on growth of human B lymphocytes; interferon-gamma prolongs the increased c-MYC mRNA levels after activation
Scand J Immunol, 33 (4), 365-73
DOI 10.1111/j.1365-3083.1991.tb01783.x, PubMed 1902001

Stokke T, Erikstein B, Holte H, Funderud S, Steen HB (1991)
Cell cycle-specific expression and nuclear binding of DNA polymerase alpha
Mol Cell Biol, 11 (6), 3384-9
DOI 10.1128/mcb.11.6.3384-3389.1991, PubMed 2038340

Stokke T, Holte H, Erikstein B, Davies CL, Funderud S, Steen HB (1991)
Simultaneous assessment of chromatin structure, DNA content, and antigen expression by dual wavelength excitation flow cytometry
Cytometry, 12 (2), 172-8
DOI 10.1002/cyto.990120212, PubMed 1710961

Publications 1990

Abrahamsen AF, Borge L, Holte H (1990)
Infection after splenectomy for Hodgkin's disease
Acta Oncol, 29 (2), 167-70
DOI 10.3109/02841869009126539, PubMed 2334569

Funderud S, Erikstein B, Asheim HC, Nustad K, Stokke T, Blomhoff HK, Holte H, Smeland EB (1990)
Functional properties of CD19+ B lymphocytes positively selected from buffy coats by immunomagnetic separation
Eur J Immunol, 20 (1), 201-6
DOI 10.1002/eji.1830200129, PubMed 1689662

Holte H (1990)
Activation of normal and neoplastic B lymphocytes
Norwegian Cancer Society, Oslo, 1 b. (flere pag.)
BIBSYS 900422793, ISBN 82-90187-63-7

Smeland EB, Holte H, Kiil Blomhoff H, Asheim HC, Stokke T, Torjesen P, Funderud S (1990)
Inhibition of polyphosphoinositide breakdown and c-myc induction accompanying inhibition of human B-cell activation by two monoclonal antibodies against the leucocyte common antigen (CD45)
Scand J Immunol, 31 (5), 583-91
DOI 10.1111/j.1365-3083.1990.tb02809.x, PubMed 1693226

Stokke T, Holte H, Davies CD, Steen HB, Lie SO (1990)
Quenching of Hoechst 33258 fluorescence in erythroid precursors
Cytometry, 11 (6), 686-90
DOI 10.1002/cyto.990110605, PubMed 1696537

Publications 1989

Holte H, Blomhoff HK, Beiske K, Funderud S, Torjesen P, Gaudernack G, Stokke T, Smeland EB (1989)
Intracellular events associated with inhibition of B cell activation by monoclonal antibodies to HLA class II antigens
Eur J Immunol, 19 (7), 1221-5
DOI 10.1002/eji.1830190711, PubMed 2547623

Holte H, de Lange Davies C, Beiske K, Stokke T, Marton PF, Smeland EB, Høie J, Kvaløy S (1989)
Ki67 and 4F2 antigen expression as well as DNA synthesis predict survival at relapse/tumour progression in low-grade B-cell lymphoma
Int J Cancer, 44 (6), 975-80
DOI 10.1002/ijc.2910440605, PubMed 2606582

Holte H, Stokke T, Smeland E, Watt R, Blomhoff HK, Kaalhus O, Ohlsson R (1989)
Levels of myc protein, as analyzed by flow cytometry, correlate with cell growth potential in malignant B-cell lymphomas
Int J Cancer, 43 (1), 164-70
DOI 10.1002/ijc.2910430130, PubMed 2642893

Publications 1988

Beiske K, Clark EA, Holte H, Ledbetter JA, Smeland EB, Godal T (1988)
Triggering of neoplastic B cells via surface IgM and the cell surface antigens CD20 and CDw40. Responses differ from normal blood B cells and are restricted to certain morphologic subsets
Int J Cancer, 42 (4), 521-8
DOI 10.1002/ijc.2910420409, PubMed 2459071

Holte H, Torjesen P, Blomhoff HK, Ruud E, Funderud S, Smeland EB (1988)
Cyclic AMP has the ability to influence multiple events during B cell stimulation
Eur J Immunol, 18 (9), 1359-66
DOI 10.1002/eji.1830180909, PubMed 2458941

Stokke T, Holte H, Steen HB (1988)
In vitro and in vivo activation of B-lymphocytes: a flow cytometric study of chromatin structure employing 7-aminoactinomycin D
Cancer Res, 48 (23), 6708-14
PubMed 3263191

Publications 1987

Holte H, Davies CD, Kvaløy S, Smeland EB, Foss-Abrahamsen A, Kaalhus O, Marton PF, Godal T (1987)
The activation-associated antigen 4F2 predicts patient survival in low-grade B-cell lymphomas
Int J Cancer, 39 (5), 590-4
DOI 10.1002/ijc.2910390508, PubMed 3106247

Holte H, Saeter G, Dahl IM, Abrahamsen AF (1987)
Progressive loss of vision in patients with high-grade non-Hodgkin's lymphoma
Cancer, 60 (10), 2521-3
DOI 10.1002/1097-0142(19871115)60:10<2521::aid-cncr2820601029>3.0.co;2-n, PubMed 3664433

Lømo J, Holte H, de Lange Davies C, Ruud E, Laukas M, Smeland EB, Godal T, Blomhoff HK (1987)
Downregulation of c-myc RNA is not a prerequisite for reduced cell proliferation, but is associated with G1 arrest in B-lymphoid cell lines
Exp Cell Res, 172 (1), 84-91
DOI 10.1016/0014-4827(87)90095-4, PubMed 3115797

Smeland EB, Beiske K, Ohlsson R, Holte H, Ruud E, Blomhoff HK, Jefferis R, Godal T (1987)
Activation of human B cells: alternate options for initial triggering and effects of nonmitogenic concentrations of anti-IgM antibodies on resting and activated cells
J Immunol, 138 (10), 3179-84
PubMed 3553323

Smeland EB, Blomhoff HK, Holte H, Ruud E, Beiske K, Funderud S, Godal T, Ohlsson R (1987)
Transforming growth factor type beta (TGF beta) inhibits G1 to S transition, but not activation of human B lymphocytes
Exp Cell Res, 171 (1), 213-22
DOI 10.1016/0014-4827(87)90264-3, PubMed 2442015

Publications 1986

Schjølseth SA, Bøhler PJ, Marton P, Holte H (1986)
[Lymphomatoid granulomatosis]
Tidsskr Nor Laegeforen, 106 (25), 2056-7, 2082
PubMed 3775730

Publications 1959

Holte H (1959)
Reguleringene i Begnavassdraget og deres innflytelse på forholdene i Ådalen
Oslo, 167 s.
BIBSYS 000869643